Biogen boosts outlook after Q3 beat on multiple sclerosis franchise

What happened

Biogen reported higher-than-expected third-quarter 2026 results, helped mainly by its multiple sclerosis franchise, and raised its full-year outlook. The company added $2.8B in revenue, about 11% growth from a year earlier, beating analyst estimates by $170M.

Confirmed

Global impact / market context

A raised outlook tells investors management expects the stronger sales trend to continue. If Biogen sells more MS and growth-portfolio drugs than expected, revenue and cash available to fund research, acquisitions, and shareholder returns can rise, supporting the stock.

Analyst inference

Biogen shares gained before the market opened after the beat and outlook boost. Investors weigh that against falling non-GAAP earnings per share, which fell about 46% to $2.62 on a $284M charge tied mainly to the RayThera acquisition, even though that figure still beat estimates.

Analyst inference

What to watch

1. Watch whether Biogen's multiple sclerosis product revenue keeps shrinking, after falling about 13% from a year earlier to $919M, while Spinraza's $461M beat supported the franchise. Confirmed
2. Track sales of Leqembi, the Alzheimer's therapy made with Eisai, which brought in $202M globally and missed the $205M estimate; continued shortfalls could limit growth expectations. Analyst inference
3. Watch whether the new drugs from the $5.6B Apellis purchase, Syfovre and Empaveli, sustain their 27% and 92% growth, since they underpin Biogen's growth portfolio. Analyst inference

Evidence

• seekingalpha.com